S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
LUCD · Lucid Diagnostics Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Lucid Diagnostics Inc (LUCD)
NASDAQ NMS - GLOBAL MARKET
Health Care
$0.34
-0.02
(-5.06%)
● At close: October 21 at 4:00:00 PM EDT
$0.33
-0.00
(-0.09%)
After-Hours:
7:18:20 PM EDT
DAY'S RANGE
$0.34
$0.32
$0.39
52-WEEK RANGE
$0.34
$0.30
$1.63
What's happening
- LUCD is down 5.06% today, trading at $0.34. — Live quote
- It's trading within 3% of its 52-week low ($0.30). (Finnhub fundamentals)
- Volume today (50,272) is well below its 3-month average of 1,606,540. (Finnhub fundamentals)
- Reports earnings on 2026-11-10 (before market open), 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.08 actual vs. $-0.07 estimated (-14.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 7
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (11 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
LUCD
-67.72%
vs S&P 500
-80.49%
1-YEAR RETURN
LUCD
-71.85%
vs S&P 500
-86.41%
6-MONTH RETURN
LUCD
-71.85%
3-MONTH RETURN
LUCD
-63.60%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.08
Est. $-0.07
MISS -14.8%
2026-04-26 (Q1 2026)
$-0.17
Est. $-0.08
MISS -100.7%
2026-01-26 (Q4 2025)
$-0.10
Est. $-0.10
BEAT +2.0%
2025-10-26 (Q3 2025)
$-0.10
Est. $-0.11
BEAT +11.0%
Valuation Measures & Ratios
Enterprise Value4$61.6M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)13.14
Price / Book718.68
EV4 / Revenue11.32
EV4 / EBITDA—
Profit Margin-959.76%
Operating Margin-950.65%
Return on Equity (ROE8)-404.34%
Return on Assets (ROA9)-125.42%
Avg Volume (3M)1,606,540
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | — | — | $105.0M | $63.8M | $76.1M |
| P/E | — | — | -1.94 | -1.17 | -1.25 |
| Price/Sales | — | — | 24.01 | 15.42 | 19.13 |
| Price/Book | — | — | 4.06 | 8.12 | -14.15 |
| EV/Revenue | — | — | 13.19 | 7.90 | 12.78 |
| EV/EBITDA | — | — | -1.24 | — | — |
| ROE | — | — | -209.46% | -696.04% | 1132.53% |
| ROA | — | — | -101.72% | -141.51% | -185.69% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short13,455,236
Change from Prior Settlement+4.87%
% of Float—
Days to Cover (Short Ratio)10.32
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 26.7% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -959.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -71.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on LUCD
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $1.2M | $1.2M | $828.0K | $1.2M | $976.0K | $1.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$12.8M | -$12.1M | -$11.8M | -$11.4M | -$12.5M | -$11.7M | -$11.2M | -$10.8M |
| Net income | -$11.7M | -$13.9M | -$10.4M | -$4.4M | -$26.9M | -$12.4M | -$11.0M | -$10.6M |
| EPS (diluted) | — | — | $-0.10 | $-0.08 | $-0.52 | $-0.25 | $-0.23 | $-0.40 |
| EPS (basic) | $-0.08 | $-0.17 | $-0.10 | $-0.08 | $-0.52 | $-0.25 | $-0.23 | $-0.40 |
| Operating margin | — | — | -$971 | -$979 | -$1.5K | -$998 | -$1.1K | -$1.1K |
| Net margin | — | — | -$859 | -$382 | -$3.2K | -$1.1K | -$1.1K | -$1.1K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $38.9M | $34.1M | $40.4M | $53.2M | $38.7M | $32.8M | $30.7M | $22.6M |
| Total liabilities | $28.0M | $30.1M | $29.5M | $27.4M | $30.8M | $38.2M | $25.3M | $16.3M |
| Stockholders' equity | $10.9M | $4.0M | $10.9M | $25.8M | $7.9M | -$5.4M | $5.4M | $6.3M |
| Total current assets | $36.6M | $31.4M | $37.5M | $49.8M | $33.8M | $27.5M | $25.1M | $16.8M |
| Total current liabilities | $27.5M | $29.4M | $28.6M | $26.2M | $29.4M | $36.6M | $23.5M | $14.2M |
| Cash & equivalents | — | — | — | $47.3M | $31.1M | $25.2M | $22.4M | $14.5M |
| Accounts receivable | $1.1M | $689.0K | $643.0K | $550.0K | $373.0K | $61.0K | $45.0K | $39.0K |
| Inventory | $484.0K | $469.0K | $353.0K | $486.0K | $505.0K | $484.0K | $341.0K | $651.0K |
| Property, plant & equipment | $810.0K | $907.0K | $809.0K | $862.0K | $948.0K | $1.0M | $1.1M | $940.0K |
| Intangible assets | $105.0K | $210.0K | $315.0K | $421.0K | $526.0K | $631.0K | $736.0K | $842.0K |
| Other non-current assets | $10.0K | $10.0K | $47.0K | $52.0K | $1.1M | $1.1M | $1.1M | $1.1M |
| Accounts payable | $667.0K | $1.1M | $970.0K | $751.0K | $833.0K | $829.0K | $1.2M | $1.1M |
| Accrued liabilities | $2.4M | $2.2M | $2.7M | — | — | — | $2.8M | — |
| Other current liabilities | — | — | — | — | — | — | — | $53.0K |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $191.0K | $165.0K | $131.0K | $131.0K | $102.0K | $84.0K | $63.0K | $52.0K |
| Retained earnings | -$312.7M | -$298.0M | -$274.3M | -$258.1M | -$247.7M | -$239.8M | -$203.8M | -$192.2M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.3M | -$12.1M | -$12.6M | -$10.9M | -$10.5M | -$12.5M | -$9.9M | -$10.2M |
| Investing cash flow | -$21.0K | -$215.0K | -$51.0K | -$28.0K | -$25.0K | -$93.0K | -$259.0K | -$350.0K |
| Financing cash flow | $16.8M | $5.5M | $2.0K | $27.1M | $16.5M | $15.4M | $18.0M | $94.0K |
| Free cash flow | -$11.3M | -$12.3M | -$12.7M | — | -$10.6M | -$12.6M | -$10.2M | — |
| Capital expenditures | $21.0K | $215.0K | $79.0K | — | $25.0K | $93.0K | $296.0K | — |
| Depreciation & amortization | $224.0K | $222.0K | $209.0K | $220.0K | $222.0K | $221.0K | $222.0K | $215.0K |
| Share-based compensation | — | — | — | $1.1M | $1.1M | $949.0K | $1.1M | $1.2M |
| Change in accounts receivable | $399.0K | $46.0K | $96.0K | $177.0K | $312.0K | $16.0K | $7.0K | -$122.0K |
| Change in accounts payable | -$411.0K | $108.0K | $220.0K | -$82.0K | $4.0K | -$412.0K | $106.0K | $233.0K |
| Tax withholding on stock comp | $0 | $17.0K | — | — | $0 | $0 | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | $4.3M | $2.4M | $377.0K | $500.0K |
| Gross profit | — | — | — | $377.0K | $500.0K |
| Operating income | -$49.6M | -$46.1M | -$48.5M | -$56.3M | -$27.4M |
| Net income | -$58.0M | -$45.5M | -$52.7M | -$56.2M | -$28.1M |
| EPS (diluted) | — | $-1.05 | $-1.26 | $-1.55 | — |
| EPS (basic) | $-0.69 | $-1.05 | $-1.26 | $-1.55 | $-1.51 |
| Operating margin | — | -$1.1K | -$2.0K | -$14.9K | -$5.5K |
| Net margin | — | -$1.0K | -$2.2K | -$14.9K | -$5.6K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $40.4M | $30.7M | $27.3M | $32.5M | $59.0M |
| Total liabilities | $29.5M | $25.3M | $29.6M | $9.5M | $4.3M |
| Stockholders' equity | $10.9M | $5.4M | -$2.3M | $23.0M | $54.7M |
| Total current assets | $37.5M | $25.1M | $22.1M | $24.4M | $57.3M |
| Total current liabilities | $28.6M | $23.5M | $29.4M | $8.4M | $4.3M |
| Cash & equivalents | — | $22.4M | $18.9M | $22.5M | $53.7M |
| Accounts receivable | $643.0K | $45.0K | $45.0K | $17.0K | $200.0K |
| Inventory | $353.0K | $341.0K | $278.0K | $111.0K | — |
| Property, plant & equipment | $809.0K | $1.1M | $1.3M | $1.6M | $971.0K |
| Intangible assets | $315.0K | $736.0K | $1.4M | $3.4M | — |
| Other non-current assets | $47.0K | $1.1M | $1.1M | $1.1M | $725.0K |
| Accounts payable | $970.0K | $1.2M | $1.1M | $1.1M | $1.5M |
| Accrued liabilities | $2.7M | $2.8M | — | — | — |
| Other current liabilities | — | — | $9.3M | $5.0M | — |
| Common stock & paid-in capital | $131.0K | $63.0K | $42.0K | $41.0K | $35.0K |
| Retained earnings | -$274.3M | -$203.8M | -$150.7M | -$98.1M | -$41.9M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$46.5M | -$44.1M | -$32.8M | -$29.7M | -$17.7M |
| Investing cash flow | -$197.0K | -$646.0K | -$221.0K | -$4.1M | -$862.0K |
| Financing cash flow | $59.0M | $48.2M | $29.5M | $2.6M | $72.1M |
| Free cash flow | -$46.7M | -$44.4M | — | -$32.9M | -$18.5M |
| Capital expenditures | $197.0K | $296.0K | — | $3.2M | $862.0K |
| Depreciation & amortization | $872.0K | $1.2M | $2.5M | $1.9M | $4.0K |
| Share-based compensation | — | $4.2M | $5.8M | $13.9M | $9.1M |
| Change in accounts receivable | $601.0K | $0 | $28.0K | -$183.0K | $200.0K |
| Change in accounts payable | -$270.0K | $96.0K | $89.0K | -$445.0K | -$665.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding LUCD as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-02-20 to 2026-05-20
Recent transactions
- Insiders have net bought 245,000 shares over the last 182 days, across 1 purchase and 0 sales.
- Most recent: Matheis Dennis (Director) — Open market purchase of 245,000 shares on 2026-05-20.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)245,000 sh(1 txns)
Sales (open market)0 sh(0 txns)
Net Shares+245,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Matheis Dennis | Director | Open market purchase | 2026-05-20 | 245,000 |
| Aklog Lishan | Chief Executive Officer | Grant / award | 2026-02-20 | 2,170,000 |
| White Debra | Director | Grant / award | 2026-02-20 | 123,000 |
| Sparks Ronald M | Director | Grant / award | 2026-02-20 | 123,000 |
| SOKOLOV JACQUE J | Director | Grant / award | 2026-02-20 | 123,000 |
| PALUMBO JOHN R | Director | Grant / award | 2026-02-20 | 123,000 |
| Lapidus Stanley | Director | Grant / award | 2026-02-20 | 123,000 |
| Cox James L | Director | Grant / award | 2026-02-20 | 123,000 |
| MCGRATH DENNIS M | Chief Financial Officer | Grant / award | 2026-02-20 | 470,000 |
| O'Neil Shaun | President and COO | Grant / award | 2026-02-20 | 620,000 |
| Gordon Michael Adam | General Counsel and Secretary | Grant / award | 2026-02-20 | 300,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-20 | Matheis Dennis | Director | Open market purchase | 245,000 | $1.00 |
| 2026-02-20 | Aklog Lishan | Chief Executive Officer | Grant / award | 2,170,000 | $0.00 |
| 2026-02-20 | Matheis Dennis | Director | Grant / award | 123,000 | $0.00 |
| 2026-02-20 | White Debra | Director | Grant / award | 123,000 | $0.00 |
| 2026-02-20 | Sparks Ronald M | Director | Grant / award | 123,000 | $0.00 |
| 2026-02-20 | SOKOLOV JACQUE J | Director | Grant / award | 123,000 | $0.00 |
| 2026-02-20 | PALUMBO JOHN R | Director | Grant / award | 123,000 | $0.00 |
| 2026-02-20 | Lapidus Stanley | Director | Grant / award | 123,000 | $0.00 |
| 2026-02-20 | Cox James L | Director | Grant / award | 123,000 | $0.00 |
| 2026-02-20 | MCGRATH DENNIS M | Chief Financial Officer | Grant / award | 470,000 | $0.00 |
| 2026-02-20 | O'Neil Shaun | President and COO | Grant / award | 620,000 | $0.00 |
| 2026-02-20 | Gordon Michael Adam | General Counsel and Secretary | Grant / award | 300,000 | $0.00 |
| 2025-08-20 | Matheis Dennis | Director | Open market purchase | 100,000 | $1.02 |
| 2025-05-22 | Matheis Dennis | Director | Open market purchase | 33,218 | $1.32 |
| 2025-05-21 | Matheis Dennis | Director | Open market purchase | 129,684 | $1.32 |
| 2025-05-20 | Matheis Dennis | Director | Open market purchase | 187,098 | $1.29 |
| 2025-02-20 | O'Neil Shaun | President and COO | Grant / award | 300,000 | $0.00 |
| 2025-02-20 | Aklog Lishan | Chief Executive Officer | Grant / award | 300,000 | $0.00 |
| 2025-02-20 | SOKOLOV JACQUE J | Director | Grant / award | 112,800 | $0.00 |
| 2025-02-20 | Lapidus Stanley | Director | Grant / award | 112,800 | $0.00 |
| 2025-02-20 | Matheis Dennis | Director | Grant / award | 112,800 | $0.00 |
| 2025-02-20 | Cox James L | Director | Grant / award | 112,800 | $0.00 |
| 2025-02-20 | MCGRATH DENNIS M | Chief Financial Officer | Grant / award | 300,000 | $0.00 |
| 2025-02-20 | Gordon Michael Adam | General Counsel and Secretary | Grant / award | 300,000 | $0.00 |
| 2025-02-20 | White Debra | Director | Grant / award | 112,800 | $0.00 |
| 2025-02-20 | Sparks Ronald M | Director | Grant / award | 112,800 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:14 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 8-K | 2026-10-12 | View on SEC.gov → |
| 2026-09-22 | 8-K | 2026-09-22 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-06-24 | 8-K | 2026-06-24 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-14 | 8-K | 2026-05-14 | View on SEC.gov → |
| 2026-05-13 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-04-24 | 8-K | 2026-04-24 | View on SEC.gov → |
| 2026-04-23 | 8-K | 2026-04-23 | View on SEC.gov → |
| 2026-03-26 | 8-K | 2026-03-26 | View on SEC.gov → |
| 2026-03-25 | 10-K | 2025-12-31 | View on SEC.gov → |
Recent news
Headlines about LUCD (Lucid Diagnostics Inc.). Links open the publisher — we don’t host full articles.
-
Lucid Diagnostics Receives Nasdaq Notice for Sub-$1 Bid Price, Faces Compliance Deadline
Kalkine Media · 2026-10-16 -
Lucid Diagnostics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
TradingView · 2026-10-16 -
LUCD 8-K & SEC Filings
Yahoo Finance · 2026-10-16 -
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
Yahoo Finance · 2026-09-22 -
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript
Yahoo Finance · 2026-08-20 -
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth
Yahoo Finance · 2026-08-15 -
PAVmed Inc. Q2 2026 Earnings Call Summary
Yahoo Finance · 2026-08-14 -
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Yahoo Finance · 2026-08-14
No headlines in this category right now — try “All”.